Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Net Margin (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Net Margin data on record, last reported at 7405.81% in Q1 2025.

  • For Q1 2025, Net Margin changed N/A year-over-year to 7405.81%; the TTM value through Sep 2025 reached 3966.42%, down 820376.0%, while the annual FY2024 figure was 5504.28%, N/A changed from the prior year.
  • Net Margin reached 7405.81% in Q1 2025 per RANI's latest filing, down from 1529.28% in the prior quarter.
  • Across five years, Net Margin topped out at 4665.34% in Q3 2022 and bottomed at 7405.81% in Q1 2025.
  • Average Net Margin over 5 years is 6.26%, with a median of 1084.49% recorded in 2023.
  • Peak YoY movement for Net Margin: plummeted -327233bps in 2023, then crashed -261377bps in 2024.
  • A 5-year view of Net Margin shows it stood at 279.7% in 2021, then surged by 1768bps to 4665.34% in 2022, then tumbled by -77bps to 1084.49% in 2023, then crashed by -241bps to 1529.28% in 2024, then crashed by -384bps to 7405.81% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 7405.81% in Q1 2025, 1529.28% in Q4 2024, and 1084.49% in Q4 2023.